During Q4 2018 the big money sentiment decreased to 1.39. That’s change of 0.06, from 2018Q3’s 1.45. 4 investors sold all, 24 reduced holdings as Simulations Plus, Inc. ratio worsened. 26 grew holdings while 13 funds acquired holdings. Funds hold 6.54 million shares thus 6.05% more from 2018Q3’s 6.16 million shares.
Prudential Financial owns 10,899 shs for 0% of their capital. Stanley invested in 63,024 shs or 0.35% of the stock. Amer Intl Gp Inc holds 7,575 shs or 0% of its capital. Legal & General Grp Plc holds 1,888 shs. Morgan Stanley invested in 35,885 shs. Geode Mngmt Limited Liability holds 128,181 shs or 0% of its capital. 65 are held by Meeder Asset Management Incorporated. Parametric Port Ltd Liability Corp holds 12,688 shs. Bnp Paribas Arbitrage Sa invested in 4 shs or 0% of the stock. Oppenheimer Asset Mgmt Inc has invested 0% of its capital in Simulations Plus, Inc. (NASDAQ:SLP). Dorsey Wright And stated it has 864 shs or 0.01% of all its holdings. Bessemer holds 0% of its capital in Simulations Plus, Inc. (NASDAQ:SLP) for 31,700 shs. Pnc Gp invested in 21,561 shs. 30,000 were accumulated by Strs Ohio. Renaissance Tech Limited Co stated it has 0.01% of its capital in Simulations Plus, Inc. (NASDAQ:SLP).
Simulations Plus, Inc. registered $1.08 million net activity with 0 insider buys and 3 sales since September 27, 2018.
On April, 8. Investors wait Simulations Plus, Inc. (NASDAQ:SLP) to reveal its quarterly earnings, according to RTT. Analysts forecast $0.10 earnings per share. That’s $0.01 down or 9.09 % from 2018’s earnings of $0.11. If earnings per share of $0.10 is announced the profit of SLP could reach $1.75 million giving it 50.28 P/E. After $0.09 EPS report last quarter, Wall Street now predicts 11.11 % EPS growth of Simulations Plus, Inc.. SLP hit $20.11 during the last trading session after $0.68 change.Currently Simulations Plus, Inc. is uptrending after 32.05% change in last March 24, 2018. SLP has also 41,272 shares volume. SLP outperformed the S&P 500 by 27.68%.
Simulations Plus, Inc. develops and sells drug discovery and development software for mechanistic modeling and simulation.The company has $351.12 million market cap. The firm offers GastroPlus, which simulates the absorption, pharmacokinetics , and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.41.04 is the P/E ratio. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor.
For more Simulations Plus, Inc. (NASDAQ:SLP) news published recently go to: Seekingalpha.com, Nasdaq.com, Zacks.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Reality About To Set In For Simulations Plus Investors; Up To 70% Decline Possible – Seeking Alpha” published on July 10, 2018, “Pre-Market Most Active for Jan 10, 2019 : BBBY, M, UXIN, IBN, AMD, NIO, TWTR, SQQQ, QQQ, AAL, TGT, NOK – Nasdaq” on January 10, 2019, “Simulations Plus (SLP) Earnings Expected to Grow: What to Know Ahead of Next Week’s Release – Zacks.com” with a publish date: January 01, 2019, “Earnings Scheduled For January 9, 2019 – Benzinga” and the last “Simulations Plus, Inc. (SLP) CEO Shawn O’Connor on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: November 14, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.